ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly share repurchase program total authorization ($M) ($M)
Form 10-Q / 10-K Shareholders' Equity Note
Latest, Q2 2026
15,000
Period ended Jun 30, 2026
Change on a year earlier
0.0%
15,000 in Q2 2025
History
11 quarters
Since Q2 2018
Sources
10
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Share repurchase program total authorization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 15,000 | 0.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 15,000 | 0.0% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 15,000 | 0.0% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 15,000 | – | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 15,000 | – | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 15,000 | – | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 15,000 | – | Form 10-K (filed 2025-02-19) ↗ |
| Q2 2021 | Jun 30, 2021 | 5,000 | – | Form 10-K (filed 2025-02-19) ↗ |
| Q4 2018 | Dec 31, 2018 | 8,000 | – | Form 10-K (filed 2019-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 8,000 | – | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2018 | Jun 30, 2018 | 8,000 | – | Form 10-K (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Eli Lilly Share repurchase program total authorization ($M) ($M), quarterly Q2 2018–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/buyback_program_auth
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.